A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques

Journal Article · Wed Apr 25 00:00:00 EDT 2007 · Virology

DOI:https://doi.org/10.1016/j.virol.2006.10.050· OSTI ID:20977016

Shimizu, Yuya ^[1]; Inaba, Katsuhisa ^[2]; Kaneyasu, Kentaro ^[2]; Ibuki, Kentaro ^[2]; Himeno, Ai ^[2]; Okoba, Masashi ^[1]; Goto, Yoshitaka ^[1]; Hayami, Masanori ^[2]; Miura, Tomoyuki ^[2]; Haga, Takeshi ^[1]

---

1. Department of Veterinary Microbiology, University of Miyazaki, Miyazaki 889-2192 (Japan)
2. Laboratory of Primate Model, Experimental Research Center for Infectious Diseases, Institute for Virus Research, Kyoto University, Kyoto 606-8507 (Japan)

Regulated-on-activation-normal-T-cell-expressed-and-secreted (RANTES), a CC-chemokine, enhances antigen-specific T helper (Th) type-1 responses against HIV-1. To evaluate the adjuvant effects of RANTES against HIV vaccine candidate in SHIV-macaque models, we genetically engineered a live-attenuated SHIV to express the RANTES gene (SHIV-RANTES) and characterized the virus's properties in vivo. After the vaccination, the plasma viral loads were same in the SHIV-RANTES-inoculated monkeys and the parental nef-deleted SHIV (SHIV-NI)-inoculated monkeys. SHIV-RANTES provided some immunity in monkeys by remarkably increasing the antigen-specific CD4{sup +} Th cell-proliferative response and by inducing an antigen-specific IFN-{gamma} ELISpot response. The magnitude of the immunity in SHIV-RANTES-immunized animals, however, failed to afford greater protection against a heterologous pathogenic SHIV (SHIV-C2/1) challenge compared to control SHIV-NI-immunized animals. SHIV-RANTES immunized monkeys, elicited robust cellular CD4{sup +} Th responses and IFN-{gamma} ELISpot responses after SHIV-C2/1 challenge. These findings suggest that the chemokine RANTES can augment vaccine-elicited, HIV-specific CD4{sup +} T cell responses.

• OSTI ID: 20977016
• Journal Information: Virology, Vol. 361, Issue 1; Other Information: DOI: 10.1016/j.virol.2006.10.050; PII: S0042-6822(06)00798-7; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0042-6822
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
AIDS VIRUS
ANTIGENS
GENES
HUMAN POPULATIONS
IMMUNITY
IN VIVO
MONKEYS
VACCINES